MarketFriction

Saamya Biotech (India) Ltd

BSE 532905 · Biotechnology
Market cap₹4.90 Cr.
Not trading

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore
Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019
Sales0.000.000.000.000.000.000.000.000.000.000.000.00
Expenses0.090.0331.610.010.010.010.010.010.010.000.010.01
Operating Profit-0.09-0.03-31.61-0.01-0.01-0.01-0.01-0.01-0.010.00-0.01-0.01
OPM %
Other Income0.000.000.000.000.000.000.000.000.000.000.000.00
Interest0.000.000.000.000.000.000.000.000.000.000.000.00
Depreciation0.230.238.690.000.000.000.000.000.000.000.000.00
Profit before tax-0.32-0.26-40.30-0.01-0.01-0.01-0.01-0.01-0.010.00-0.01-0.01
Tax %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Net Profit-0.31-0.25-40.30-0.01-0.01-0.01-0.01-0.01-0.010.00-0.01-0.01
EPS in Rs-0.12-0.10-16.20-0.00-0.00-0.00-0.00-0.00-0.000.00-0.00-0.00
Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016TTM
Sales0.000.000.000.002.3516.2823.292.9814.0330.2115.120.00
Expenses0.000.000.000.002.3215.8522.713.2413.6929.9815.250.03
Operating Profit0.000.000.000.000.030.430.58-0.260.340.23-0.13-0.03
OPM %1.28%2.64%2.49%-8.72%2.42%0.76%-0.86%
Other Income0.000.000.000.000.00-0.120.65-0.04-0.050.030.110.00
Interest0.000.000.000.000.000.040.810.030.020.000.000.00
Depreciation0.000.000.000.000.000.070.070.070.121.000.920.00
Profit before tax0.000.000.000.000.030.200.35-0.400.15-0.74-0.94-0.03
Tax %33.33%55.00%20.00%-2.50%40.00%-6.76%-53.19%
Net Profit0.000.000.000.000.020.090.28-0.400.10-0.68-0.44-0.03
EPS in Rs0.000.000.010.040.11-0.160.04-0.27-0.180.00
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth%-1%72%-50%
Compounded Profit Growth%%-22%25%
Stock Price CAGR-12%%%%
Return on Equity0%-1%-1%-2%
Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Equity Capital8.088.0823.0923.0923.0923.0924.8824.8824.8824.8824.88
Reserves0.000.911.501.417.208.828.708.784.493.813.37
Borrowings0.000.571.000.120.160.220.380.354.433.633.24
Other Liabilities0.330.030.280.162.887.7016.7319.1110.7740.6247.84
Total Liabilities8.419.5925.8724.7833.3339.8350.6953.1244.5772.9479.33
Fixed Assets0.010.350.610.701.641.371.521.3811.8010.669.54
CWIP0.570.000.000.0027.8128.7529.0229.3418.2518.2518.25
Investments0.000.008.230.010.010.000.000.000.000.000.00
Other Assets7.839.2417.0324.073.879.7120.1522.4014.5244.0351.54
Total Assets8.419.5925.8724.7833.3339.8350.6953.1244.5772.9479.33
Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Cash from Operating Activity-7.45-1.03-2.22-3.850.39-0.74-1.01-0.19-0.220.620.08
Cash from Investing Activity-0.58-0.44-13.654.70-6.18-0.85-0.51-0.290.500.170.31
Cash from Financing Activity8.031.4716.04-0.985.811.561.520.45-0.27-0.80-0.39
Net Cash Flow0.000.000.17-0.130.02-0.030.00-0.030.010.000.00
Free Cash Flow-8.03-1.37-2.49-3.94-2.36-1.60-1.52-0.480.280.790.39
CFO/OP1,300%-172%-174%73%-65%270%-62%
Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Debtor Days365.00183.40287.742,573.37342.37521.581,211.36
Inventory Days0.000.000.000.000.000.000.00
Days Payable
Cash Conversion Cycle365.00183.40287.742,573.37342.37521.581,211.36
Working Capital Days138.2339.9149.37374.8093.4038.7872.42
ROCE %0.00%0.00%0.00%0.11%1.15%3.54%-0.97%0.65%-2.33%-3.29%
Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017
Promoters35.67%27.63%27.23%25.62%25.62%25.62%
Public64.33%72.37%72.77%74.38%74.38%74.38%
No. of Shareholders10,54810,59210,80610,7749,79210,553

Fundamentals

Market Cap₹ 4.90 Cr.
Current Price₹ 1.97
Book Value₹ -5.39
ROCE-3.29 %
ROE-1.93 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-50%
Compounded Profit Growth (TTM)25%
Standalone figures.
Valuation
P/E, 3-year average28.37x
P/B, 3-year average0.24x
P/E, 5-year average28.89x
P/B, 5-year average0.21x
Profitability
Operating margin (excl. other income)-0.86%
Operating margin (incl. other income)-0.13%
EBITDA margin5.82%
Pre-tax margin-0.26%
Net profit margin-0.26%
ROE-1.55%
ROCE-2.95%
ROA-0.58%
ROE, 3-year average-1.19%
ROCE, 3-year average-1.56%
ROA, 3-year average-0.51%
ROE, 5-year average-0.78%
ROCE, 5-year average-0.45%
ROA, 5-year average-0.34%
ROIC (approx.)-0.06%
Tax rate53.19%
Other income / net worth0.39%
Growth
Sales growth (latest year)-49.95%
Sales CAGR, 3 years71.84%
Sales CAGR, 5 years-1.47%
Per share
EPS (TTM)Rs -0.02
EPS (latest year)Rs -0.18
EPS (latest quarter)Rs -0.00
EPS, 3-year averageRs -0.14
EPS, 5-year averageRs -0.09
Book value per shareRs 11.35
Sales per shareRs 6.08
Cash flow per shareRs 0.03
Free cash flow per shareRs 0.16
Efficiency
Asset turnover0.19x
Fixed asset turnover1.58x
Debtor days1211 days
Debtors turnover0.30x
Cash conversion cycle1211 days
Working capital days72 days
Leverage
Total debtRs 3 Cr
Cash and bankRs 0 Cr
Net debtRs 3 Cr
Debt to equity0.11x
Net debt / EBITDA3.66x
Owners' fund to total sources35.61%
Debt to assets4.08%
Cash flow
Cash from Operating Activity (latest year)Rs 0 Cr
Cash from Investing Activity (latest year)Rs 0 Cr
Cash from Financing Activity (latest year)Rs -0 Cr
Free cash flow (latest year)Rs 0 Cr
FCFE (approx.: FCF + change in debt)Rs 0 Cr
Sales to cash flow189.00x
Statement figures
Net sales (TTM)Rs 15 Cr
Net sales (latest year)Rs 15 Cr
Operating profit excl. other income (latest year)Rs -0 Cr
Operating profit (latest quarter)Rs -0 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 1 Cr
PBDT (TTM)Rs 1 Cr
Profit before tax (TTM)Rs -0 Cr
Tax (latest year)Rs -0 Cr
Net profit (TTM)Rs -0 Cr
Net profit (latest year)Rs -0 Cr
Net profit (latest quarter)Rs -0 Cr
Depreciation (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 14 Cr
Total expenditure (latest year)Rs 15 Cr
Total income (latest year)Rs 15 Cr
Share capitalRs 25 Cr
ReservesRs 3 Cr
Shareholders' fundsRs 28 Cr
Total assetsRs 79 Cr
Net blockRs 10 Cr
Capital work in progressRs 18 Cr
ReceivablesRs 50 Cr
Other liabilitiesRs 48 Cr
Shares outstanding (crore)2.49
Ownership
Promoter holding25.62% (-2.01 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
Not enough price history.

Red flags

F-score 5 of 8
explainReceivables outrunning sales Receivables grew 16% vs sales -50% in 2016
lookRepeated losses Net loss in each of the last two years
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2019
Sales ₹0 Cr. Net loss ₹0 Cr.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Anthem Biosciences Ltd48,99682.630.4 %
Advanced Enzyme Technologies Ltd3,15220.014.0 %
CCME Global Ltd208-2.92 %
Vivo Bio Tech Ltd367.74 %
Shree Ganesh Biotech India Ltd191.31 %
Genomic Valley Biotech Ltd98861.02 %
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Saamya Biotech (India) Ltd?

Saamya Biotech (India) Ltd (532905) has a market capitalisation of Rs 4.90 Cr. at the close.

What were Saamya Biotech (India) Ltd's latest quarterly results?

In the Jun 2019 quarter, Saamya Biotech (India) Ltd sales was Rs 0 Cr with a net loss of Rs 0 Cr.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03